Zukunftsfonds Heilbronn has led a €60m funding round for Germany-based Eleva, a biotechnology company that uses a moss-based platform to develop proteins for use in potential drug candidates.
Zukunftsfonds Heilbronn leads €60m round for Eleva
Most Popular
